A phase III study of late course accelerated hyperfractionated radiotherapy versus conventionally fractionated radiotherapy in patients with nasopharyngeal carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 6, 2012, Pages 600-605

  Pan, Zi Qiang ^a,b   He, Xia Yun ^a,b   Guo, Xiao Mao ^a,b   Ye, Ming ^a,b   Zhang, Zhen ^a,b   He, Shao Qin ^a,b   Liu, Tai Fu ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

accelerated hyperfractionated radiotherapy; nasopharyngeal carcinoma; radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE NECROSIS; BRACHYTHERAPY; BRAIN INJURY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONVENTIONALLY FRACTIONATED RADIOTHERAPY; CRANIAL NERVE PARALYSIS; DENTAL CARIES; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEARING IMPAIRMENT; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; LATE COURSE ACCELERATED HYPERFRACTIONATED RADIOTHERAPY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; NERVE INJURY; OVERALL SURVIVAL; PATIENT SAFETY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SURVIVAL RATE; SURVIVAL TIME; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; CARCINOMA; CENTRAL NERVOUS SYSTEM; DOSE FRACTIONATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUCOSITIS; NASOPHARYNGEAL NEOPLASMS; RADIATION DOSAGE; RADIATION INJURIES; RADIOTHERAPY; STATISTICS, NONPARAMETRIC; WEIGHT LOSS; YOUNG ADULT;

EID: 84870254016     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31822dfd55     Document Type: Article

References (31)

1. Yeh SA, Tang Y, Lui CC, et al. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2005;62:672-679. (Pubitemid 40779753)
2. Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005;61:1107-1116. (Pubitemid 40340904)
3. Gao YS, Hu CS, Ying HM, et al. Treatment results of nasopharyngeal carcinoma: A retrospective analysis of 1837 cases in a single institute. Chin J Radiat Oncol. 2008;17:335-339.
4. Waldron J, Warde P, Irish J, et al. A dose escalation study of hyperfractionated accelerated radiation delivered with integrated neck surgery (HARDWINS) for the management of advanced head and neck cancer. Radiother Oncol. 2008;87:173-180.
5. Franchin G, Vaccher E, Talamini R, et al. Nasopharyngeal cancer WHO type II-III monoinstitutional retrospective analysis with standard and accelerated hyperfractionated radiation therapy. Oral Oncol. 2002;38:137-144. (Pubitemid 34168196)
6. Nomiya T, Nemoto K, Wada H, et al. Advantage of accelerated fractionation regimens in definitive radiotherapy for stage II glottic carcinoma. Ann Otol Rhinol Laryngol. 2006;115:727-732. (Pubitemid 44582866)
7. Jereczek-Fossa BA, Morra A, DeBraud F, et al. Hyperfractionated radiotherapy in locally advanced nasopharyngeal cancer. An analysis of 43 consecutive patients. Strahlenther Onkol. 2004; 180:425-433. (Pubitemid 39207381)
8. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet. 2006;368:843-845.
9. Horiot JC, Le Fur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of EORTC cooperative group of radiotherapy. Radiother Oncol. 1992;25:231-241. (Pubitemid 23000765)
10. Fu KK, Pajak TF, Trotti A, et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoma: First report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7-16. (Pubitemid 30488207)
11. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet. 2006;368:843-854. (Pubitemid 44292807)
12. He XY, Liu TF, He SQ, et al. Late course accelerated hyperfractionated radiotherapy of nasopharyngeal carcinoma (LCAF). Radiother Oncol. 2007;85:29-35.
13. Zhao KL, Wang Y, Shi XH. Late course accelerated hyperfractionated radiotherapy for clinical T1-2 esophageal carcinoma. World J Gastroenterol. 2003;9:1374-1376. (Pubitemid 36805687)
14. Butler EB, Teh BS, Grant WH 3rd, et al. SMART (Simultaneous Modulated Accelerated Radiation Therapy) boost: A new accelerated fractiona schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 1999;45:21-32. (Pubitemid 29380070)
15. Zhu XD, Wei JB, Qu S, et al. Comparison of remote results of conventional fractionation radiotherapy and late course accelerated hyperfractionation radiotherapy for nasopharyngeal carcinoma. Chin J Radiat Oncol. 2007;16:321-324.
16. Waldron J, Tin MM, Keller A, et al. Limitation of conventional two dimensional radiation therapy planning in nasopharyngeal carcinoma. Radiother Oncol. 2003;68:153-161. (Pubitemid 38367548)
17. Chau RM, Teo PM, Kam MK, et al. Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: To treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord. Med Dosim. 2007; 32:263-270. (Pubitemid 350016880)
18. Teo PM, Leung SF, Chan AT, et al. Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurogic complications. Int J Radiat Oncol Biol Phys. 2000;48:1311-1322.
19. Sun Y, Mao YP, Ma J, et al. Influences of magnetic resonance imaging on the staging system of nasopharyngeal carcinoma. Ai Zheng. 2007;26:158-163.
20. Chung NN, Ting LL, Hsu WC, et al. Impact of magnetic resonance imaging versus CT on nasopharyngeal carcinoma: Primary tumor target delineation for radiotherapy. Head Neck. 2004;26:241-246.
21. Liao XB, Mao YP, Liu LZ, et al. How does magnetic resonance imaging influence staging according to AJCC staging system for nasopharyngeal carcinoma compared with computed tomography? Int J Radiat Oncol Biol Phys. 2008;72:1368-1377.
22. Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27:3684-3690.
23. Tham IW, Hee SW, Yeo RM, et al. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre Singapore experience. Int J Radiat Oncol Biol Phys. 2009;75:1481-1486.
24. Lin S, Pan J, Han L. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: Report on the 3-year outcome of a prospective series. Int J Radiat Oncol Biol Phys. 2009;75:1071-1078.
25. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup Study 0099. J Clin Oncol. 1998;16:1310-1317. (Pubitemid 28175745)
26. Brizel DM. Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma. Semin Radiat Oncol. 1998;8:237-246. (Pubitemid 28460808)
27. Lu H, Peng L, Yuan X, et al. Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A treatment paradigm also applicable to patients in Southeast Asia. Cancer Treat Rev. 2009;35:345-353.
28. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 2005;23:3568-3576.
29. Chua DT, Wei WI, Wong MP, et al. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck. 2008;30:863-867. (Pubitemid 352008945)
30. Kao J, Genden EM, Gupta V, et al. Phase 2 trial of concurrent 5-fluorourail, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer. Cancer. 2011;117:318-326.
31. Gunn GB, Endres EJ, Parker B, et al. A phase I/II study of altered fractionated IMRT alone for intermediated T-stage oropharyngeal carcinoma. Strahlenther Onkol. 2010;186:489-495.